Home World News Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard... World News Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 523 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR De qué manera el seguimiento de los síntomas mejora la atención... May 6, 2021 Teen With Cancer On Dream Trip To NASA Gets Surprise Call... May 9, 2019 Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide... January 14, 2022 GreaterGood’s Mask Donations Are Helping Wildlife Sanctuaries Continue Their Essential Work September 10, 2020 Load more HOT NEWS Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of... Spotlight On: Occupational Therapists in Cancer Care Adjuvant Atezolizumab Plus Bevacizumab Improves RFS Among Patients at High Risk... 6-Year-Old Uses Money From Lemonade Stand To Take Mom Out On...
